You are here: Industry Insights > Bebtelovimab

News List

FDA grants EUA to Lilly’s bebtelovimab for Covid-19 treatment Pharmaceutical-Technology
February 15, 2022
Bebtelovimab is indicated for treating mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above.
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 WorldPharmaNews
February 14, 2022
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly and Company (NYSE: LLY) announced today.
Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options FirstWordPharma
February 11, 2022
Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million.
FDA Approves New Antibody Drug to Fight Omicron Variant drugs.com
February 11, 2022
The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the omicron variant.
FDA Grants Emergency Use Authorization for New Antibody Drug drugs.com
February 11, 2022
The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the Omicron variant.